Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on April 11, 2022. The filing discloses the approval and execution of amended and restated employment agreements with three executive officers: Yuval Cohen (CEO), Sean Moran (CFO), and Craig Millian (COO). The agreements are effective as of April 11, 2022, and expire on April 11, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
| Executive Officer | Annual Base Salary | Target Annual Bonus | Agreement Term |
|---|---|---|---|
| Yuval Cohen (CEO) | $598,850 | Up to 60% of base salary | 2 years |
| Sean Moran (CFO) | $428,490 | Up to 40% of base salary | 2 years |
| Craig Millian (COO) | $428,490 | Up to 40% of base salary | 2 years |
Material Changes
The material change reported is the formalization of new employment terms for the company's top three executives. These agreements replace prior arrangements and establish specific compensation structures, severance packages, and non-compete provisions effective April 11, 2022.
Outlook, Risks, and Unusual Items
Severance and Change in Control Provisions:
- Standard Termination: If terminated without cause or for good reason outside a Change in Control Period, executives are eligible for 12 months of base salary (CEO) or 12 months (CFO/COO), plus COBRA coverage and a pro-rated bonus.
- Change in Control Period: If termination occurs within 3 months prior to or 12 months following a change in control, severance increases to 24 months of base salary for the CEO and 18 months for the CFO and COO. Additionally, all outstanding equity awards accelerate, and the current year bonus is paid at 2x target for the CEO and 1x target for the CFO and COO.
- Golden Parachute Reduction: Severance payments are subject to reduction if necessary to avoid excise taxes under Internal Revenue Code Section 4999.
- Restrictive Covenants: All executives are subject to non-compete provisions (6 months post-employment) and non-solicitation provisions (12 months post-employment), contingent on receiving severance.
Risks: The filing highlights the financial obligation of the company to pay significant severance and accelerate equity vesting in the event of a change in control or termination without cause.
Investor Verification Checklist
- Verify the total potential cash and equity payout obligations in the event of a Change in Control for each executive.
- Review the attached Exhibits 10.1, 10.2, and 10.3 for the full legal text of the employment agreements.
- Assess the impact of the 6-month non-compete clauses on the company's ability to retain talent or hire competitors.
- Confirm the company's current cash position to ensure it can meet potential severance obligations if triggered.